Adagrasib

Major

Adagrasib Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Adagrasib Dasatinib Phyrago An increased risk of QT interval prolongation, increased exposure to CYP3A4 substrates Details Adagrasib Degarelix Injection Firmagon An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Deutetrabenazine Austedo An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Digoxin Cardoxin® Increased exposure to P-gp substrates and an increased risk of P-gp substrates-related adverse effects Details Adagrasib Disopyramide Norpace An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Docetaxel Beizray Increased DOCEtaxel exposure Details Adagrasib Docetaxel Injection Beizray Increased DOCEtaxel exposure Details Adagrasib Dofetilide Tikosyn Increased dofetilide exposure and an increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachy... Details Adagrasib Dolasetron Anzemet An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Dolasetron Injection Anzemet An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Adagrasib Elacestrant Orserdu Increased CYP3A4 substrate exposure Details Adagrasib Encorafenib Braftovi An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Entrectinib Rozlytrek An increased risk of QT interval prolongation, increased exposure to CYP3A4 substrates Details Adagrasib Erdafitinib Balversa Increased erdafitinib exposure Details Adagrasib Eribulin Injection Halaven An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Everolimus Afinitor Increased exposure to CYP3A/P-gp substrates Details Adagrasib Famotidine Calmicid An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Famotidine Injection Calmicid An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Felbamate Felbatol An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Felodipine Plendil® Increased CYP3A4 substrate exposure Details Adagrasib Flecainide Tambocor® An increased risk of QT interval prolongation, increased exposure to CYP2D6 substrates Details Adagrasib Foscarnet Injection Foscavir An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Futibatinib Lytgobi Increased futibatinib exposure and increased risk of futibatinib-related adverse reactions Details Adagrasib Galantamine Razadyne An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Gemifloxacin Factive An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Glasdegib Daurismo An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Goserelin Implant Zoladex An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Granisetron Injection Granisol An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Histrelin Implant Supprelin An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Hydroxychloroquine Plaquenil An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Ibrexafungerp Brexafemme Increased CYP3A4 substrate exposure Details Adagrasib Ibrutinib Imbruvica Increased CYP3A4 substrate exposure Details Adagrasib Inotuzumab Ozogamicin Injection Besponsa An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Ivabradine Corlanor An increased risk of QT interval prolongation, increased exposure to CYP3A4 substrates Details Adagrasib Ketoconazole Topical Extina® Foam Increased adagrasib exposure and an increased risk of adagrasib-related adverse effects, increased ketoconazole exposure, an incre... Details Adagrasib Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions and an increased risk of QT interval prolon... Details